Eli Casdin backs Codexis' platform tech with $50M equity buy
About a month after Codexis notched a deal with Novartis $NVS, the California company $CDXS on Thursday said long-time investor Casdin Capital is putting up $50 million in a private placement, which puts the New York-based investment firm in control of more than 5% of the protein engineering player’s stock.
Eli Casdin started his eponymous investment firm in 2012 and dates his relationship with Codexis back to at least a decade. About three years ago, Casdin Capital began investing in the industrial biotech company, after it pivoted its focus to the life sciences — under the auspices of new chief John Nicols — away from the energy industry.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.